Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.20
ALQA's Cash-to-Debt is ranked lower than
84% of the 815 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.13 vs. ALQA: 0.20 )
Ranked among companies with meaningful Cash-to-Debt only.
ALQA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05  Med: No Debt Max: No Debt
Current: 0.2
Equity-to-Asset 0.58
ALQA's Equity-to-Asset is ranked lower than
58% of the 746 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. ALQA: 0.58 )
Ranked among companies with meaningful Equity-to-Asset only.
ALQA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.57  Med: 0.82 Max: 0.99
Current: 0.58
0.57
0.99
Piotroski F-Score: 4
Altman Z-Score: -5.09
Beneish M-Score: -3.31
WACC vs ROIC
13.32%
-62.12%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -152.61
ALQA's Operating Margin % is ranked lower than
88% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.94 vs. ALQA: -152.61 )
Ranked among companies with meaningful Operating Margin % only.
ALQA' s Operating Margin % Range Over the Past 10 Years
Min: -1119.69  Med: -320.39 Max: -51.07
Current: -152.61
-1119.69
-51.07
Net Margin % -145.99
ALQA's Net Margin % is ranked lower than
88% of the 768 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.26 vs. ALQA: -145.99 )
Ranked among companies with meaningful Net Margin % only.
ALQA' s Net Margin % Range Over the Past 10 Years
Min: -1222.3  Med: -316.99 Max: -52.73
Current: -145.99
-1222.3
-52.73
ROE % -64.09
ALQA's ROE % is ranked lower than
90% of the 792 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.83 vs. ALQA: -64.09 )
Ranked among companies with meaningful ROE % only.
ALQA' s ROE % Range Over the Past 10 Years
Min: -312.57  Med: -69.44 Max: -16.22
Current: -64.09
-312.57
-16.22
ROA % -40.92
ALQA's ROA % is ranked lower than
87% of the 820 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.57 vs. ALQA: -40.92 )
Ranked among companies with meaningful ROA % only.
ALQA' s ROA % Range Over the Past 10 Years
Min: -796.05  Med: -57.1 Max: -15.45
Current: -40.92
-796.05
-15.45
ROC (Joel Greenblatt) % -988.15
ALQA's ROC (Joel Greenblatt) % is ranked lower than
91% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.97 vs. ALQA: -988.15 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ALQA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -53854.55  Med: -1376.37 Max: -55.94
Current: -988.15
-53854.55
-55.94
3-Year Revenue Growth Rate 37.30
ALQA's 3-Year Revenue Growth Rate is ranked higher than
93% of the 641 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.20 vs. ALQA: 37.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ALQA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 37.3
Current: 37.3
0
37.3
3-Year EBITDA Growth Rate -31.80
ALQA's 3-Year EBITDA Growth Rate is ranked lower than
94% of the 604 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.20 vs. ALQA: -31.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ALQA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -67.6  Med: 24.1 Max: 108.9
Current: -31.8
-67.6
108.9
3-Year EPS without NRI Growth Rate -28.20
ALQA's 3-Year EPS without NRI Growth Rate is ranked lower than
87% of the 580 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.20 vs. ALQA: -28.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ALQA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 20.5 Max: 115
Current: -28.2
0
115
GuruFocus has detected 2 Warning Signs with Alliqua BioMedical Inc $ALQA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ALQA's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2899
Compare:OTCPK:INNV, NAS:NVGN, OTCPK:SUWN, NAS:IMNP, AMEX:AXN, AMEX:CPHI, OTCPK:CHEXD, OTCPK:INBP, NAS:BSPM, NAS:TNXP, NAS:PRPH, OTCPK:ECTE, OTCPK:ENZB, NAS:OASM, AMEX:NNVC, NAS:ALIM, OTCPK:CKDXF, NAS:NBRV, NAS:ZGNX, NAS:RMTI » details
Traded in other countries:HL1A.Germany,
Headquarter Location:USA
Alliqua BioMedical Inc is a functional regeneration company providing wound care solutions. It is also engaged in contract manufacturing.

Alliqua BioMedical Inc a Florida corporation formed on October 21, 1997. It is a biomedical company through its subsidiary providing wound care solutions. The Company's core business includes; wound care and contract manufacturing. The Company develops, manufactures and markets high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. Its subsidiary manufactures and markets its hydrogel products. Its products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies. Together, these technologies enable it to produce gels that can satisfy rigid tolerance specifications with respect to a range of physical characteristics (e.g., thickness, water content, adherence, absorption, moisture vapor transmission rate (a measure of the passage of water vapor through a substance) and release rate) while maintaining product integrity. In July 2012, it began to market two proprietary products, SilverSeal, a hydrogel wound dressing with silver coated fibers, and Hydress, an over-the-counter hydrogel wound dressing. It supplies these gels mainly to the wound care segment of the healthcare industry. The Company's SilverSeal and Hydress dressings are each currently available in two sizes and are used to provide and maintain a moist wound environment. SilverSeal dressings also provide an antimicrobial barrier. On November 14, 2013 Company entered into a license, marketing and development agreement with Anthrogenesis Corporation, Celgene Cellular Therapeutics (CCT), an affiliate of Celgene Corporation, pursuant to which CCT granted an exclusive, royalty-bearing license in its intellectual property related to certain placental based products, including the wound care products Extracellular Matrix (ECM), a suite of wound management products made from extracellular matrix derived from the human placenta and Biovance, a collagen-based decellularized and dehydrated topical wound covering produced from human amniotic membrane for the management of non-infected partial- and full-thickness wounds; and also into a supply agreement with CCT, pursuant to which CCT will supply Company with the entire requirement of Biovance for distribution and sale in the United States. The Company's medical devices are subject to the U.S. Food and Drug Administration's general controls, which include compliance with the applicable portions of the U.S. Food and Drug Administration's Quality System Regulation, facility registration and product listing, reporting of adverse medical events, and appropriate, truthful and non-misleading labeling, advertising, and promotional materials. It is subject to various laws and governmental regulations concerning environmental matters and employee safety and health in the U.S. and other countries.

Top Ranked Articles about Alliqua BioMedical Inc

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Alliqua BioMedical, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
Alliqua BioMedical, Inc. Announces Partnership with Partners Capital Group to Provide UltraMIST® Customers with New Equipment Financing Programs
Alliqua BioMedical, Inc. Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Requirement
Alliqua BioMedical, Inc. Announces Preliminary First Quarter Fiscal 2017 Revenue and Updates Fiscal Year 2017 Outlook; Earnings Conference Call Scheduled for May 9, 2017
Alliqua BioMedical, Inc. to Present New Data at the Spring 2017 Symposium on Advanced Wound Care
Alliqua BioMedical, Inc. Announces Closing of Approximately $3.8 Million Public Offering
Alliqua BioMedical, Inc. Announces Proposed Public Offering of Common Stock

YARDLEY, Pa., March 28, 2017 (GLOBE NEWSWIRE) -- Alliqua BioMedical, Inc. (NASDAQ:ALQA) ("Alliqua" or "the Company"), a regenerative technologies company committed to restoring tissue and rebuilding lives, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Alliqua also expects to grant the underwriter a 30-day option to purchase additional shares of its common stock to cover over-allotments, if any.
Rodman & Renshaw, a unit of H.C. Wainwright & Co., is acting as the sole underwriter for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The Company intends to use the net proceeds from this offering primarily for working capital and general corporate purposes, and to pay the Company’s monthly payment obligations under its credit agreement with Perceptive Credit Opportunities Fund, L.P. A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission ("SEC") and was declared effective on September 25, 2014. A preliminary prospectus supplement describing the terms of the offering will be filed with the SEC and will form a part of the effective registration statement. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available, from H.C. Wainwright & Co., LLC, 430 Park Avenue 4th Floor, New York, NY 10022, or by calling (646) 975-6957 or by emailing [email protected] or at the SEC's website at http://www.sec.gov. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Alliqua BioMedical, Inc. Alliqua is a regenerative technologies company committed to restoring tissue and rebuilding lives. Through its sales and distribution network, together with its proprietary products, Alliqua offers solutions that allow clinicians to utilize the latest advances in regenerative technologies to bring improved patient outcomes to their practices. Alliqua currently markets the human biologic regenerative technologies, Biovance® and Interfyl™. The Company also markets its Mist Therapy System®, which uses painless, noncontact low-frequency ultrasound to stimulate cells below the wound bed to promote the healing process. In addition to these technologies, Alliqua markets its line of dressings for wound care under the SilverSeal® and Hydress® brands, as well as its TheraBond 3D® advanced dressing which incorporates the TheraBond 3D® Antimicrobial Barrier Systems technology. In addition, Alliqua can provide a custom manufacturing solution to partners in the medical device and cosmetics industry, utilizing its hydrogel technology. The Company has locations in Yardley, Pennsylvania, Langhorne, Pennsylvania and Eden Prairie, Minnesota. For additional information, please visit http://www.alliqua.com. To receive future press releases via email, please visit http://ir.stockpr.com/alliqua/email-alerts.  Legal Notice Regarding Forward-Looking Statements: This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of our control that can make such statements untrue, including, but not limited to, our expectations on the completion, timing and size of the public offering and the anticipated use of proceeds therefrom, the adequacy of the Company’s liquidity to pursue its complete business objectives; inadequate capital; the Company’s ability to obtain reimbursement from third party payers for its products; loss or retirement of key executives; adverse economic conditions or intense competition; loss of a key customer or supplier; entry of new competitors and products; adverse federal, state and local government regulation; technological obsolescence of the Company’s products; technical problems with the Company’s research and products; the Company’s ability to expand its business through strategic acquisitions; the Company’s ability to integrate acquisitions and related businesses; price increases for supplies and components; and the inability to carry out research, development and commercialization plans.  In addition, other factors that could cause actual results to differ materially are discussed in our filings with the SEC, including our most recent Annual Report on Form 10-K filed with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise.
Investor Relations:
Westwicke Partners on behalf of Alliqua BioMedical, Inc.
Mike Piccinino, CFA 1-443-213-0500
[email protected]

Read more...
Alliqua BioMedical, Inc. Announces the Publication of a Peer-reviewed Study Examining the Use of MIST Therapy for Deep Tissue Pressure Injuries

YARDLEY, Pa., March 20, 2017 (GLOBE NEWSWIRE) -- Alliqua BioMedical, Inc. (NASDAQ:ALQA) ("Alliqua" or "the Company"), a regenerative technologies company committed to restoring tissue and rebuilding lives, today announced the publication of a peer-reviewed study examining the use of MIST Therapy for deep tissue pressure injuries (“DTPIs”).
A pressure injury, also known as a bedsore or a decubitus ulcer, is a localized injury to the skin and/or underlying tissues that usually occurs over a bony prominence as a result of pressure. A deep tissue pressure injury is a form of pressure injury that occurs to the tissues under intact skin.  The November/December 2016 edition of the academic journal, Wound Repair & Regeneration, featured a longitudinal prospective historical case control study by Honaker et al., titled “The Effect of Adjunctive Noncontact Low Frequency Ultrasound on Deep Tissue Pressure Injury.”  A total of 60 subjects with deep tissue pressure injuries were enrolled in the study, which included a control group consisting of 30 subjects and a treatment group of 30 subjects. DTPIs in the control group were treated with the standard of care, while those in the treatment group were treated with noncontact low frequency ultrasound therapy, or MIST Therapy, in addition to the standard of care. The results of the study demonstrated that DTPIs treated with MIST Therapy in addition to the standard of care had significantly improved outcomes, compared to DTPIs treated with the standard of care alone. 17% of the DTPIs within the treatment group were resolved, as compared to 0% in the control group. Furthermore, the treatment group showed a mean decrease in DTPI total surface area of 8.8cm2, representing a 50% reduction in injury size, as compared to a mean decrease of 0.3cm2, or 2% reduction in injury size, in the control group. Importantly, only 6.6% of the wounds treated with MIST Therapy progressed to a negative outcome, compared to 63.3% in the control group. “The annual incidence of pressure injuries nationwide is reported to be 4.4 million, and approximately 400,000 of these injuries are DTPIs,” said Nino Pionati, Chief Strategy and Marketing Officer of Alliqua BioMedical. “Treating DTPIs with the current standard of care alone can often result in the development of complex Stage 3 or 4 pressure injuries, which can cost in excess of $120,000 to treat. With this fact in mind, the findings of this study not only demonstrate the clinical effectiveness of MIST Therapy in treating DTPIs, but also serve to highlight the potential cost savings to the healthcare system that can be realized by utilizing MIST Therapy in addition to the standard of care.” About Alliqua BioMedical, Inc. Alliqua is a regenerative technologies company committed to restoring tissue and rebuilding lives. Through its sales and distribution network, together with its proprietary products, Alliqua offers solutions that allow clinicians to utilize the latest advances in regenerative technologies to bring improved patient outcomes to their practices. Alliqua currently markets the human biologic regenerative technologies, Biovance® and Interfyl™. The Company also markets its MIST Therapy System®, which uses painless, noncontact low-frequency ultrasound to stimulate cells below the wound bed to promote the healing process. In addition to these technologies, Alliqua markets its line of dressings for wound care under the SilverSeal® and Hydress® brands, as well as its TheraBond 3D® advanced dressing which incorporates the TheraBond 3D® Antimicrobial Barrier Systems technology. In addition, Alliqua can provide a custom manufacturing solution to partners in the medical device and cosmetics industry, utilizing its hydrogel technology. The Company has locations in Yardley, Pennsylvania, Langhorne, Pennsylvania and Eden Prairie, Minnesota. For additional information, please visit http://www.alliqua.com. To receive future press releases via email, please visit http://ir.stockpr.com/alliqua/email-alerts. Legal Notice Regarding Forward-Looking Statements: This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of our control that can make such statements untrue, including, but not limited to, the adequacy of the Company’s liquidity to pursue its complete business objectives; inadequate capital; the Company’s ability to obtain reimbursement from third party payers for its products; loss or retirement of key executives; adverse economic conditions or intense competition; loss of a key customer or supplier; entry of new competitors and products; adverse federal, state and local government regulation; technological obsolescence of the Company’s products; technical problems with the Company’s research and products; the Company’s ability to expand its business through strategic acquisitions; the Company’s ability to integrate acquisitions and related businesses; price increases for supplies and components; and the inability to carry out research, development and commercialization plans.  In addition, other factors that could cause actual results to differ materially are discussed in our filings with the SEC, including our most recent Annual Report on Form 10-K filed with the SEC, and our most recent Form 10-Q filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise.
Investor Relations:
Westwicke Partners on behalf of Alliqua BioMedical, Inc.
Mike Piccinino, CFA 1-443-213-0500
[email protected]

Read more...
Alliqua BioMedical, Inc. to Announce Fourth Quarter and Fiscal Year 2016 Results on March 7th

YARDLEY, Pa., March 01, 2017 (GLOBE NEWSWIRE) -- Alliqua BioMedical, Inc. (NASDAQ:ALQA) ("Alliqua" or "the Company"), a regenerative technologies company committed to restoring tissue and rebuilding lives, today announced plans to release fourth quarter and fiscal year 2016 financial results after the market closes on March 7th.
Chief Executive Officer, David Johnson, and Chief Financial Officer, Brian Posner, will host a teleconference at 5:00 p.m. Eastern Time on March 7th to discuss the results of the quarter and to host a question and answer session. Those interested in participating on the call may dial 800-474-8920 (719-325-2249 for international callers) and provide access code 6277436 approximately 10 minutes prior to the start time. A live webcast of the call will be made available on the investor relations section of the Company’s website at http://ir.alliqua.com. For those unable to participate, a replay of the call will be available for two weeks at 888-203-1112 (719-457-0820 for international callers); access code 6277436. The webcast will be archived on the investor relations section of Alliqua’s website. About Alliqua BioMedical, Inc. Alliqua is a regenerative technologies company committed to restoring tissue and rebuilding lives. Through its sales and distribution network, together with its proprietary products, Alliqua offers solutions that allow clinicians to utilize the latest advances in regenerative technologies to bring improved patient outcomes to their practices. Alliqua currently markets the human biologic regenerative technologies, Biovance® and Interfyl®. The Company also markets its Mist Therapy System®, which uses painless, noncontact low-frequency ultrasound to stimulate cells below the wound bed to promote the healing process. In addition to these technologies, Alliqua markets its line of dressings for wound care under the SilverSeal® and Hydress® brands, as well as its TheraBond 3D® advanced dressing which incorporates the TheraBond 3D® Antimicrobial Barrier Systems technology. In addition, Alliqua can provide a custom manufacturing solution to partners in the medical device and cosmetics industry, utilizing its hydrogel technology. The Company has locations in Yardley, Pennsylvania, Langhorne, Pennsylvania and Eden Prairie, Minnesota. For additional information, please visit http://www.alliqua.com. To receive future press releases via email, please visit http://ir.stockpr.com/alliqua/email-alerts.
Investor Relations:
Westwicke Partners on behalf of Alliqua Biomedical, Inc.
Mike Piccinino, CFA 1-443-213-0500
[email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 0.40
ALQA's PB Ratio is ranked higher than
97% of the 769 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.84 vs. ALQA: 0.40 )
Ranked among companies with meaningful PB Ratio only.
ALQA' s PB Ratio Range Over the Past 10 Years
Min: 0.37  Med: 1.39 Max: 23.18
Current: 0.4
0.37
23.18
PS Ratio 0.49
ALQA's PS Ratio is ranked higher than
91% of the 741 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. ALQA: 0.49 )
Ranked among companies with meaningful PS Ratio only.
ALQA' s PS Ratio Range Over the Past 10 Years
Min: 0.49  Med: 10.14 Max: 38.71
Current: 0.49
0.49
38.71
EV-to-EBIT -0.81
ALQA's EV-to-EBIT is ranked lower than
99.99% of the 563 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.94 vs. ALQA: -0.81 )
Ranked among companies with meaningful EV-to-EBIT only.
ALQA' s EV-to-EBIT Range Over the Past 10 Years
Min: -20.5  Med: -2.6 Max: -0.5
Current: -0.81
-20.5
-0.5
EV-to-EBITDA -0.96
ALQA's EV-to-EBITDA is ranked lower than
99.99% of the 591 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.60 vs. ALQA: -0.96 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALQA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -99.1  Med: -2.8 Max: -0.5
Current: -0.96
-99.1
-0.5
Current Ratio 0.43
ALQA's Current Ratio is ranked lower than
97% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.44 vs. ALQA: 0.43 )
Ranked among companies with meaningful Current Ratio only.
ALQA' s Current Ratio Range Over the Past 10 Years
Min: 0.04  Med: 1.79 Max: 96.93
Current: 0.43
0.04
96.93
Quick Ratio 0.29
ALQA's Quick Ratio is ranked lower than
97% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.85 vs. ALQA: 0.29 )
Ranked among companies with meaningful Quick Ratio only.
ALQA' s Quick Ratio Range Over the Past 10 Years
Min: 0.04  Med: 1.42 Max: 96.93
Current: 0.29
0.04
96.93
Days Inventory 165.19
ALQA's Days Inventory is ranked lower than
72% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 118.03 vs. ALQA: 165.19 )
Ranked among companies with meaningful Days Inventory only.
ALQA' s Days Inventory Range Over the Past 10 Years
Min: 11.87  Med: 63.83 Max: 165.19
Current: 165.19
11.87
165.19
Days Sales Outstanding 55.32
ALQA's Days Sales Outstanding is ranked higher than
68% of the 655 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.05 vs. ALQA: 55.32 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALQA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 13.55  Med: 44.64 Max: 73.9
Current: 55.32
13.55
73.9
Days Payable 125.43
ALQA's Days Payable is ranked higher than
78% of the 603 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.27 vs. ALQA: 125.43 )
Ranked among companies with meaningful Days Payable only.
ALQA' s Days Payable Range Over the Past 10 Years
Min: 24.61  Med: 123.53 Max: 196.17
Current: 125.43
24.61
196.17

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -37.20
ALQA's 3-Year Average Share Buyback Ratio is ranked lower than
92% of the 477 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.30 vs. ALQA: -37.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALQA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -67.2  Med: -16.1 Max: 30.3
Current: -37.2
-67.2
30.3

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.05
ALQA's Price-to-Median-PS-Value is ranked higher than
99% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.08 vs. ALQA: 0.05 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ALQA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.05  Med: 0.99 Max: 3.45
Current: 0.05
0.05
3.45
Earnings Yield (Greenblatt) % -122.93
ALQA's Earnings Yield (Greenblatt) % is ranked lower than
98% of the 819 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.98 vs. ALQA: -122.93 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ALQA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -212.7  Med: -38.4 Max: -4.9
Current: -122.93
-212.7
-4.9

More Statistics

Revenue (TTM) (Mil) $18.88
EPS (TTM) $ -0.96
Beta0.97
Short Percentage of Float2.30%
52-Week Range $0.32 - 1.30
Shares Outstanding (Mil)45.98

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 21 26 32
EPS ($) -0.52 -0.19 -0.09
EPS without NRI ($) -0.52 -0.19 -0.09
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ALQA

Headlines

Articles On GuruFocus.com
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Alliqua BioMedical, Inc. for Poten Jun 22 2017 
Alliqua BioMedical, Inc. Announces Partnership with Partners Capital Group to Provide UltraMIST® Jun 19 2017 
Alliqua BioMedical, Inc. Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Apr 12 2017 
Alliqua BioMedical, Inc. Announces Preliminary First Quarter Fiscal 2017 Revenue and Updates Fiscal Apr 06 2017 
Alliqua BioMedical, Inc. to Present New Data at the Spring 2017 Symposium on Advanced Wound Care Apr 05 2017 
Alliqua BioMedical, Inc. Announces Closing of Approximately $3.8 Million Public Offering Apr 03 2017 
Alliqua BioMedical, Inc. Announces Proposed Public Offering of Common Stock Mar 28 2017 
Alliqua BioMedical, Inc. Announces the Publication of a Peer-reviewed Study Examining the Use of MIS Mar 20 2017 
Alliqua BioMedical, Inc. to Announce Fourth Quarter and Fiscal Year 2016 Results on March 7th Mar 01 2017 
CFO of Alliqua BioMedical Inc Buys 2,500 Shares Aug 12 2015 

More From Other Websites
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Alliqua BioMedical, Inc. for... Jun 22 2017
Alliqua BioMedical, Inc. Announces Partnership with Partners Capital Group to Provide UltraMIST®... Jun 19 2017
ETFs with exposure to Alliqua BioMedical, Inc. : June 6, 2017 Jun 06 2017
Alliqua BioMedical, Inc. :ALQA-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 May 12 2017
Alliqua reports 1Q loss May 09 2017
Alliqua BioMedical, Inc. Reports First Quarter of Fiscal Year 2017 Financial Results May 09 2017
Investor Network: Alliqua, Inc. to Host Earnings Call May 09 2017
Alliqua BioMedical, Inc. Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price... Apr 12 2017
Alliqua BioMedical, Inc. Announces Preliminary First Quarter Fiscal 2017 Revenue and Updates Fiscal... Apr 06 2017
Alliqua BioMedical, Inc. to Present New Data at the Spring 2017 Symposium on Advanced Wound Care Apr 05 2017
Alliqua BioMedical, Inc. Announces Closing of Approximately $3.8 Million Public Offering Apr 03 2017
Alliqua BioMedical, SCANA Drop into Wednesday’s 52-Week Low Club Mar 29 2017
Orexigen Posts Wider-than-Expected Loss in Q4; Sales Up Y/Y Mar 29 2017
Alliqua BioMedical, Inc. Announces Pricing of Public Offering of Common Stock Mar 29 2017
Alliqua BioMedical, Inc. Announces Proposed Public Offering of Common Stock Mar 28 2017
ETFs with exposure to Alliqua BioMedical, Inc. : March 27, 2017 Mar 27 2017
Ultragenyx's Seizure Candidate UX007 Fails in Phase II Study Mar 23 2017
Alliqua BioMedical, Inc. :ALQA-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017 Mar 21 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}